SCHEMBL2490668

SCHEMBL2490668

CCOC(=O)c1cccc(NC(=O)c2cccnc2Cl)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.67
POLB P06746 2/20 0.67
PKM P14618 1/20 0.67
NPC1 O15118 5/20 0.64
SMN1; SMN2 Q16637 4/20 0.64
HPGD P15428 1/20 0.64
MAPT P10636 6/20 0.59
ALDH1A1 P00352 5/20 0.59
KMT2A Q03164 4/20 0.59
MEN1 O00255 3/20 0.59
ABCB1 P08183 1/20 0.59
HTT P42858 1/20 0.59
ABCG2 Q9UNQ0 1/20 0.59
MAPK1 P28482 2/20 0.56
LMNA P02545 2/20 0.56
HSD17B10 Q99714 1/20 0.56
TP53 P04637 3/20 0.54
THRB P10828 1/20 0.54
TSHR P16473 1/20 0.54
PPIA P62937 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1815768 0.88 MEN1 (0.62) RAB9APOLBPKMNPC1SMN1; SMN2
SCHEMBL2417590 0.87 NPC1 (0.65) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL20080799 0.86 ALDH1A1 (0.54) RAB9APOLBPKMNPC1SMN1; SMN2
SCHEMBL18314216 0.86 ALDH1A1 (0.54) RAB9APOLBPKMNPC1SMN1; SMN2
SCHEMBL2484277 0.85 MAPT (0.53) RAB9APOLBPKMNPC1SMN1; SMN2
SCHEMBL2011651 0.83 RAB9A (0.77) RAB9APOLBPKMNPC1SMN1; SMN2
SCHEMBL4958404 0.82 CYP2C19 (0.51) RAB9APOLBPKMNPC1SMN1; SMN2
SCHEMBL1805499 0.82 MEN1 (0.67) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL1814793 0.82 MEN1 (0.67) RAB9ANPC1SMN1; SMN2HPGDMAPT
SCHEMBL31171406 0.81 RAB9A (0.63) RAB9APOLBPKMNPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3312177-B1 TRICYCLIC DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ONCONIC THERAPEUTICS INC (KR) 2021-04-14 EP disclosed
EP-3312177-B1 TRICYCLIC DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ONCONIC THERAPEUTICS INC (KR) 2021-04-14 EP disclosed
US-10464919-B2 Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same JE IL PHARMACEUTICAL CO., LTD. (KR) 2019-11-05 US disclosed
US-20180162834-A1 Tricyclic Derivative Compound, Method for Preparing Same, and Pharmaceutical Composition Comprising Same ONCONIC THERAPEUTICS INC. (KR) 2018-06-14 US disclosed
US-20180162834-A1 Tricyclic Derivative Compound, Method for Preparing Same, and Pharmaceutical Composition Comprising Same ONCONIC THERAPEUTICS INC. (KR) 2018-06-14 US disclosed
CN-104557691-B A kind of 3 amine acyl bishydrazide derivatives and its preparation method and application 中国农业大学 2017-10-24 CN disclosed
CN-104610140-B 3-amine acylhydrazone derivative, preparation method and application of 3-amine acylhydrazone derivative 青岛农业大学 2017-01-25 CN disclosed
WO-2016200101-A2 TRICYCLIC DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 제일약품주식회사 2016-12-15 WO disclosed
CN-104610140-A 3-amine acylhydrazone derivative, preparation method and application of 3-amine acylhydrazone derivative UNIV QINGDAO AGRICULTURAL 2015-05-13 CN disclosed
CN-104557691-A 3-aminoacyl bishydrazide derivatives, and preparation method and application thereof UNIV CHINA AGRICULTURAL 2015-04-29 CN disclosed
US-8815891-B2 Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same JE IL PHARMACEUTICAL CO., LTD. (KR) 2014-08-26 US disclosed
US-8815891-B2 Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same JE IL PHARMACEUTICAL CO., LTD. (KR) 2014-08-26 US disclosed
EP-2364983-B1 NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME JEIL PHARMACEUTICAL CO LTD (KR) 2013-10-23 EP disclosed
EP-2364983-B1 NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME JEIL PHARMACEUTICAL CO LTD (KR) 2013-10-23 EP disclosed
CN-102245612-A Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same JE IL PHARMACEUTICAL CO LTD 2011-11-16 CN disclosed
EP-2364983-A2 NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Jeil Pharmaceutical Co., Ltd. (KR) 2011-09-14 EP disclosed
EP-2364983-A2 NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Jeil Pharmaceutical Co., Ltd. (KR) 2011-09-14 EP disclosed
US-20110218193-A1 NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME JE IL PHARMACEUTICAL CO., LTD. (KR) 2011-09-08 US disclosed
US-20110218193-A1 NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME JE IL PHARMACEUTICAL CO., LTD. (KR) 2011-09-08 US disclosed
US-20110218193-A1 NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME JE IL PHARMACEUTICAL CO., LTD. (KR) 2011-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162834-A1 Tricyclic Derivative Compound, Method for Preparing Same, and Pharmaceutical Composition Comprising Same TNKS, TNKS2, PARP1 RAB9A 4372/4885POLB 235/4885PKM 539/4885
US-20110218193-A1 NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME PARP1, PARP15, PARP11 RAB9A 3767/4885POLB 32/4885PKM 558/4885
US-10464919-B2 Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same TNKS, TNKS2, PARP1 RAB9A 4372/4885POLB 235/4885PKM 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.